People: Acasti Pharma Inc (ACST.O)

ACST.O on Consolidated Issue listed on NASDAQ Capital Market

0.44USD
21 Nov 2014
Price Change (% chg)

$0.00 (+1.15%)
Prev Close
$0.44
Open
$0.46
Day's High
$0.46
Day's Low
$0.43
Volume
147,096
Avg. Vol
312,712
52-wk High
$1.62
52-wk Low
$0.35

Search Stocks

Waksal, Harlan 

Brief Biography

Dr. Harlan W. Waksal, M.D., serves as Executive Executive Vice President - Business and Scientific Affairs, Director of Acasti Pharma Inc., Dr. Harlan W. Waksal is a retired physician. Dr. Waksal is the Vice-President, Business and Scientific Affairs at Acasti. He received his B.A. from Oberlin College and M.D. from Tufts University School of Medicine, and his post graduate training in Internal Medicine and in Pathology. In addition, he did research in immunology at the Weizmann Institute of Science. Dr. Waksal was a founder of Imclone Systems Incorporated; a New York based pharmaceutical company specializing in developing new treatment for various forms of cancer. He served as the Chief Operating Officer and member of the Board of Directors from 1986 until 2001 and as President/CEO from 2001 until 2002. During his tenure, he was responsible for building the scientific and operation infrastructure of the company. Dr. Waksal is the author of over 50 scientific publications and has been the author of multiple patents and patent applications. His current activities are focused on managing various real estate developments and serving on select Board of Directors. Dr. Waksal currently serves on the Boards of the Oberlin College, Senesco Technologies, Inc. He also serves on the Advisory Board of Northern Rivers Funds.

Basic Compensation

Total Annual Compensation, CAD Long-Term Incentive Plans, CAD All Other, CAD Fiscal Year Total, CAD
70,500 -- 183,581 1,219,480

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Jerald Wenker

--

Andre Godin

89,100

Pierre Lemieux

479,813

Harlan Waksal

1,219,480

Tina Sampalis

101,975

Ronald Denis

--
As Of 27 Feb 2014
Search Stocks